BLA 017881 · Draximage
Technetium Tc 99m Albumin Aggregated Kit
Technetium Tc-99m Albumin Aggregated Kit · Injection
Last checked: Nov 20, 2026Latest source record: Dec 1, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Dec 30, 1987
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
30
5 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 13, 2024.
DRAXIMAGE MAA, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adult patients. DRAXIMAGE MAA, after radiolabeling with sodium pertechnetate Tc 99m, is a radioactive diagnostic agent indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. (1) Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adults. (1)
Mechanism: Following intravenous injection, more than 80% of the technetium Tc 99m albumin aggregated particles is trapped in the pulmonary alveolar capillary bed within 5 minutes. Following intraperitoneal injection, technetium Tc 99m albumin aggregated mixes with the peritoneal fluid. Clearance from the peritoneal cavity varies from insignificant, which may occur with complete shunt blockage, to very rapid clearance with subsequent transfer into the systemic circulation when the shunt is patent.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 30, 1987 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT · TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT N/A · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Albumin Aggregated Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective17
- off label use3
- product preparation issue3
- pruritus3
- radioisotope uptake increased3
- accidental underdose2
- dyspnoea2
- product distribution issue2
- product preparation error2
- rash2
- urticaria2
- anaphylactic reaction1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 4 |
Recalls
1 FDA enforcement reports for this application.
Jun 16, 2022 · Class II · Terminated
Lack of Assurance of Sterility: Out-of-specification test results obtained for Endotoxin testing.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Draximage
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.